Clinical trials: Palmoplantar Pustulosis
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Generalized Pustular Psoriasis
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).
- Trial name
- NCT05512598
- Testing
- HB0034
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Generalized Pustular Psoriasis
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
- Trial name
- NCT06886009
- Testing
- Spevigo®
- Where
- 4 sites in South Korea
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis (PPP)
A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet.
- Trial name
- NCT07270003
- Testing
- Ivarmacitinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
- Trial name
- GPP (NCT03619902)
- Testing
- Imsidolimab
- Where
- 13 sites in United States, Poland and 2 more
- Volunteers
- 8 people
- Sponsor
- Vanda Pharmaceuticals
Generalized Pustular Psoriasis, Generalized Pustular Psoriasis (GPP)
Generalized Pustular Psoriasis Registry in Costa Rica
The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national…
- Trial name
- NCT07448428
- Where
- Costa Rica
- Volunteers
- 50 people
- Sponsor
- Caja Costarricense de Seguro Social
Pustular Psoriasis (PP)
International Rare And Severe Psoriasis Expert Network
This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.
- Trial name
- IRASPEN (NCT04359394)
- Testing
- biological sampling, Phenotypic description, Photography
- Where
- 8 sites in Germany, Italy and 4 more
- Volunteers
- 180 people
- Sponsor
- University Hospital, Basel, Switzerland
Psoriasis
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT03022045
- Testing
- risankizumab
- Where
- 9 sites in Japan
- Volunteers
- 18 people
- Sponsor
- AbbVie
Palmoplantaris Pustulosis
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
The purpose of this study is to assess the efficacy, safety, and tolerability of CNTO 1959 following subcutaneous administration in participants with palmoplantar pustulosis.
- Trial name
- NCT01845987
- Testing
- CNTO 1959
- Where
- 8 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.
- Trial name
- NCT02641730
- Testing
- Guselkumab
- Where
- 32 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis, Generalized Pustular Psoriasis
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical…
- Trial name
- NCT04566471
- Testing
- prevalence/incidence
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-1 (NCT05352893)
- Testing
- 750 mg Imsidolimab, 300 mg Imsidolimab
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 45 people
- Sponsor
- Vanda Pharmaceuticals
Psoriasis, Palmoplantaris Pustulosis
Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis
The purpose of this study is to determine if Alefacept is effective in the treatment of palmar plantar pustulosis.
- Conditions
- Psoriasis, Palmoplantaris Pustulosis, Pustular Psoriasis of Palms and Soles, Pustulosis Palmaris et Plantaris
- Trial name
- NCT00301002
- Testing
- Alefacept
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- The Guenther Dermatology Research Centre
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau
Anakinra for Inflammatory Pustular Skin Diseases
Background: Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the immune system attacks the bodys tissues.
- Conditions
- Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
- Trial name
- NCT01794117
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Generalized Pustular Psoriasis
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP).
- Trial name
- NCT05239039
- Testing
- spesolimab
- Where
- 12 sites in China
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
Biologic Therapy for Generalized Pustular Psoriasis
The investigators aim to compare the efficacy and safety of secukinumab and ustekinumab in patients with generalized pustular psoriasis (GPP), and to explore the impact of genetic mutation types on clinical efficacy.
- Trial name
- NCT06391996
- Testing
- After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Chao Ji
Psoriasis
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Trial name
- NCT06952465
- Testing
- Deucravacitinib, Any biologic treatment for psoriasis
- Where
- 2 sites in Japan
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb